Loading...
Market
What will be the regulatory approval status of Liraglutide (Victoza) for Alzheimer's treatment by end of 2026?
2
Resolution / Starting Odds
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
FDA, EMA, and other major regulatory bodies' official announcements
Story
Novo Nordisk's GLP-1 Drug Liraglutide (Victoza) Shows Potential in Slowing Alzheimer's Progression
Jul 30, 2024, 11:14 AM
Novo Nordisk's older GLP-1 drug, liraglutide, commonly used for managing diabetes and weight loss, appears to slow cognitive decline in Alzheimer's patients. According to Phase 2b clinical trial data presented at the Alzheimer's Association International Conference 2024, the drug may protect the brain and slow disease progression. The study, published on Tuesday, showed that liraglutide, known commercially as Victoza, yielded mixed results in a small mid-stage study but indicated a potential to slow the loss of brain volume in people with mild Alzheimer's disease.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by both FDA and EMA • 25%
Not approved • 25%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
Yes • 50%
No • 50%
